浏览全部资源
扫码关注微信
1.安徽中医药大学,合肥 230000
2.安徽医科大学,合肥 230000
3.安徽中医药大学 第二附属医院,合肥 230000
裴蓓,硕士,从事中医药防治脾胃病研究,E-mail:18356051572@163.com
李学军,硕士,教授,主任医师,从事中医药防治脾胃病相关研究,E-mail:lixujun0308@126.com
纸质出版日期:2022-06-20,
网络出版日期:2022-05-06,
收稿日期:2021-12-12,
扫 描 看 全 文
裴蓓,温子昂,杨琦等.慢性萎缩性胃炎患者肠化或异型增生的影响因素分析及预测模型的建立[J].中国实验方剂学杂志,2022,28(12):148-154.
PEI Bei,WEN Zi-ang,YANG Qi,et al.Influencing Factors of Intestinal Metaplasia or Atypical Hyperplasia in Chronic Atrophic Gastritis Patients and Prediction Model Establishment[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(12):148-154.
裴蓓,温子昂,杨琦等.慢性萎缩性胃炎患者肠化或异型增生的影响因素分析及预测模型的建立[J].中国实验方剂学杂志,2022,28(12):148-154. DOI: 10.13422/j.cnki.syfjx.20221294.
PEI Bei,WEN Zi-ang,YANG Qi,et al.Influencing Factors of Intestinal Metaplasia or Atypical Hyperplasia in Chronic Atrophic Gastritis Patients and Prediction Model Establishment[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(12):148-154. DOI: 10.13422/j.cnki.syfjx.20221294.
目的
2
探讨慢性萎缩性胃炎(CAG)患者发生肠化或异型增生的影响因素,同时构建其预测模型。
方法
2
收录2016年6月至2021年6月在安徽中医药大学第二附属医院脾胃科收治的335例CAG患者的临床病例资料及实验室检查资料。通过SPSS 26.0中单因素及多因素Logistic回归分析方法确定CAG患者发生肠化或异型增生的影响因素,根据影响因素构建CAG患者发生肠化或异型增生的预测模型;另选取2019年6月至2021年6月于安徽医科大学第一附属医院就诊并确诊的115例CAG患者作为外部验证样本对构建的预测模型的预测效能进行验证评估。
结果
2
多因素Logistic回归分析显示,胃蛋白酶原Ⅰ[比值比(OR) 0.994,95%置信区间(95% CI) (0.990,0.999),
P
<
0.05]、病灶数量[OR 6.765,95% CI(3.831,11.945),
P
<
0.01]及幽门螺杆菌(Hp)感染[OR 0.546,95% CI(0.335,0.888),
P
<
0.05]是CAG患者发生肠化或异型增生的独立影响因素。构建出CAG患者发生肠化或异型增生的预测模型公式为
P
=-1.558+0.606×Hp感染-0.006×胃蛋白酶原Ⅰ含量+1.912×病灶数量。受试者工作特征(ROC)曲线显示,曲线下面积为0.76,约登指数为0.443,最佳截断值为0.52,敏感度为0.533,特异度为0.910。将验证组患者相关因素的数据代入预测模型进行验证,利用决策曲线分析法(DCA)检验该模型的预测效能,结果证实,模型拟合优度好,预测价值高。
结论
2
胃蛋白酶原Ⅰ、病灶数量及Hp感染是CAG患者肠化或异型增生的独立影响因素,据此构建的预测模型拟合优度好,预测价值高,可以为CAG患者病情分级及其个体化治疗方案的制定提供依据。
Objective
2
To investigate the influencing factors of intestinal metaplasia or atypical hyperplasia in chronic atrophic gastritis (CAG) patients and establish a prediction model.
Method
2
The clinical records and laboratory examination data of 335 CAG patients treated in the department of gastroenterology of the Second Affiliated Hospital of the Anhui University of Chinese Medicine from June 2016 to June 2021 were collected. Single and multiple Logistic regression analyses were used to explore the influencing factors of intestinal metaplasia or atypical hyperplasia in CAG patients by SPSS 26.0. A prediction model was constructed based on the data of the related influencing factors. In addition
115 CAG patients diagnosed in the First Affiliated Hospital of Anhui Medical University from June 2019 to June 2021 were selected as external validation samples to verify and evaluate the prediction efficiency of the constructed prediction model.
Result
2
Multiple Logistic regression analysis showed that pepsinogen Ⅰ[odds ratio(OR) 0.994,95% confidence interval(CI) (0.990,0.999),
P
<
0.05],the number of focus[OR 6.765,95% CI(3.831,11.945),
P
<
0.01], and
Helicobacter pylori
(Hp) infection[OR 0.546,95% CI(0.335,0.888),
P
<
0.05] were independent risk factors for intestinal metaplasia or atypical hyperplasia in CAG patients(
P
<
0.05). The formula of the prediction model is as follows:
P
=-1.558+0.606×Hp infection-0.006×pepsinogen Ⅰ+1.912×the number of focus. The receiver operating characteristic (ROC) curve showed the specific parameters as below: the area under the ROC curve of 0.76,the Youden index of 0.443,the best cut-off value of 0.52,sensitivity of 0.533,and specificity of 0.910. The prediction model was applied to the data of patients in the validation group for validation,and the predictive efficiency of the model was tested by decision curve analysis (DCA). The results showed that the model had a good fit and high predictive value.
Conclusion
2
Pepsinogen Ⅰ,the number of focus, and Hp infection are independent risk factors for intestinal metaplasia or atypical hyperplasia in CAG patients. The prediction model constructed based on these factors has a good fit and high predictive value,which can provide references for the classification of CAG patients and the formulation of individual treatment protocols.
慢性萎缩性胃炎肠化异型增生影响因素预测模型
chronic atrophic gastritisintestinal metaplasiaatypical hyperplasiainfluencing factorsprediction model
YIN J,YI J,YANG C,et al.Weiqi decoction attenuated chronic atrophic gastritis with precancerous lesion through regulating microcirculation disturbance and HIF-1α signaling pathway[J].Evid Based Complement Alternat Med,2019,2019:2651037.
CORREA P.Human gastric carcinogenesis:a multistep and multifactorial process—First American Cancer Society award lecture on cancer epidemiology and prevention[J].Cancer Res,1992,52(24):6735-6740.
DE VRIES A C,VAN GRIEKEN N C ,LOOMAN C W,et al.Gastric cancer risk in patients with premalignant gastric lesions:A nationwide cohort study in the Netherlands[J].Gastroenterology,2008,134(4):945-952.
SONG H,EKHEDEN I G,ZHENG Z,et al.Incidence of gastric cancer among patients with gastric precancerous lesions:Observational cohort study in a low risk western population[J].BMJ,2015,351:h3867.
ZHANG L,LIU Y,YOU P,et al.Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up[J].Scand J Gastroenterol,2018,53(7):843-848.
赵吉梅,王焕君,王连忠,等.80例慢性萎缩性胃炎伴肠上皮化生10年随访分析[J].中国医学工程,2010,18(2):75-76.
RUGGE M,GENTA R M.Staging and grading of chronic gastritis[J].Hum Pathol,2005,36(3):228-233.
中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
李莉,朱蕾蕾,孙祝美,等.慢性萎缩性胃炎中医证型分布及幽门螺杆菌感染、胃黏膜病理变化情况分析[J].上海中医药杂志,2019,52(6):20-23.
赵志敏.慢性萎缩性胃炎中医证型分布及其与IL-10、PG的关系[J].四川中医,2021,39(7):62-64.
赵晓丹,孙静晶,周斌.慢性萎缩性胃炎中医证型分布规律[J].环球中医药,2015,8(1):18-21.
MASSIRONI S,ZILLI A,ELVEVI A,et al.The changing face of chronic autoimmune atrophic gastritis:An updated comprehensive perspective[J].Autoimmun Rev,2019,18(3):215-222.
李琼慧,许建明,蔡永萍,等.慢性萎缩性胃炎的随访研究[J].安徽医科大学学报,2021,56(10):1646-1650.
陈国斌,黄蔚,蔡美珠.血清胃蛋白酶原亚群在老年胃癌及其胃癌前病变诊断中的意义[J].中国实用医药,2008,3(12):5-6.
黄妙灵,刘序友.慢性萎缩性胃炎病理改变与幽门螺旋杆菌感染及血清胃蛋白酶原、胃泌素-17的相关性[J].实用医学杂志,2020,36(20):2838-2842.
丁婷婷,侯晓婷,印睿,等.胃蛋白酶原及胃泌素17对胃癌及癌前病变的诊断价值[J].中国临床研究,2021,34(3):350-353.
冯娟.血清胃蛋白酶原与幽门螺旋杆菌筛查对胃癌早期诊断的临床价值分析[J].实用临床医药杂志,2018,22(19):21-24.
黄锦成,张斐,王佳.血清PG、G-17、Hp-IgG抗体联合检测在胃癌诊断中的临床价值分析[J].黑龙江医药,2021,34(4):949-951.
ADAMU M A,WECK M N,GAO L,et al.Incidence of chronic atrophic gastritis:Systematic review and Meta-analysis of follow-up studies[J].Eur J Epidemiol,2010,25(7):439-448.
程吉来.血清胃蛋白酶原、胃泌素-17与慢性萎缩性胃炎的关系研究[J].中国现代药物应用,2021,15(7):50-52.
胡掌朝,安俊丽,程帅师,等.慢性萎缩性胃炎患者Hp感染与IL-8、PCT、TNF-α表达水平及严重程度的关系分析[J].热带医学杂志,2021,21(6):731-734.
CORREA P,PIAZUELO M B.Evolutionary history of the Helicobacter pylori genome:Implications for gastric carcinogenesis[J].Gut Liver,2012,6(1):21-28.
KODAMA M,OKIMOTO T,OGAWA R,et al.Endoscopic atrophic classification before and after H.pylori eradication is closely associated with histological atrophy and intestinal metaplasia[J].Endosc Int Open,2015,3(4):E311-E317.
WANG J,XU L,SHI R,et al.Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication:A Meta-analysis[J].Digestion,2011,83(4):253-260.
CHEN H N,WANG Z,LI X,et al.Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia:Evidence from a Meta-analysis[J].Gastric Cancer,2016,19(1):166-175.
ITO M,TAKATA S,TATSUGAMI M,et al.Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy:A systematic review[J].J Gastroenterol,2009,44(5):365-371.
LEE Y C,CHIANG T H,CHOU C K,et al.Association between Helicobacter pylori eradication and gastric cancer incidence:A systematic review and Meta-analysis[J].Gastroenterology,2016,150(5):1113-1124.e5.[PubMed链接]
范衡.糖脂代谢紊乱与慢性萎缩性胃炎的相关性[D].乌鲁木齐:新疆医科大学,2016.
丁伟.血清CA724、CA199、癌胚抗原及血脂指标与慢性萎缩性胃炎的相关性[J].中国卫生工程学,2021,20(2):272-273,275.
于思妙,李志婷.血清CEA、CA199、CA724、血脂与慢性萎缩性胃炎相关性分析[J].世界最新医学信息文摘:连续型电子期刊,2019,19(92):198-199.
0
浏览量
10
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构